FDA Clocks IQIRVO Review Time for Patent Perks
Published Date: 8/26/2025
Notice
Summary
The FDA has officially set the review period for IQIRVO, a human drug product, so its patent can be extended. This helps the company behind IQIRVO get extra time to protect their invention after going through the FDA’s approval process. If you’re involved in drug patents or development, this means important deadlines and opportunities to keep an invention exclusive just got clearer.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA Sets Patent-Extension Review Period
The FDA has determined the regulatory review period for the drug IQIRVO so the patent holder can apply for a patent extension. If you work in drug development or hold the IQIRVO patent, this lets the company seek extra time to keep the invention exclusive after FDA review.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in